Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase II trial to study the effectiveness of combination chemotherapy in treating patients with newly diagnosed metastatic Ewing's sarcoma or primitive neuroectodermal tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Collaborator: Children's Cancer Group
• Treatments: Amifostine; Cobalt; Cyclophosphamide; Doxorubicin; Etoposide; Ifosfamide; Liposomal doxorubicin; Topotecan; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Newly diagnosed, pathologically confirmed Ewing's sarcoma or primitive neuroectodermal tumor (PNET)

• Diagnosis established from biopsy of primary tumor Light microscopy (hematoxylin and eosin stained) consistent with Ewing's sarcoma or PNET

• No immunohistochemical or ultrastructural characteristics inconsistent with Ewing's sarcoma or PNET or suggestive of rhabdomyosarcoma

• Metastatic disease required

• Biopsy of radiographically questionable metastases (e.g., pulmonary lesions) required

• Chest wall tumor with separate pleural mass considered metastatic

• No positive pleural fluid cytology alone

PATIENT CHARACTERISTICS:

• Age: 30 and under

• Absolute neutrophil count greater than 1,200/mm3

• Platelet count greater than 120,000/mm3

• Bilirubin less than 1.5 mg/dL

• AST/ALT less than 3 times normal

• Creatinine normal for age

• Significant renal abnormality/disease eligible only if nuclear GFR is normal and study coordinator approves

• Echocardiogram or MUGA normal

PRIOR CONCURRENT THERAPY:

• No prior chemotherapy or radiotherapy

• Resection at diagnosis is discouraged but does not exclude